Quick Answer
Oruka Therapeutics, Inc. reported Stockholders Equity of $471.93 million for fiscal year 2025.
Oruka Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $471.93M | +23.5% |
| 2024 | $382.22M | +38222000.0% |
| 2024 | $1.0K | -100.0% |
| 2023 | $37.02M | -11.2% |
| 2022 | $41.67M | -18.4% |
| 2021 | $51.04M | +9.7% |
| 2020 | $46.52M | +511.3% |
| 2019 | $7.61M | +26.2% |
| 2018 | $6.03M | -41.3% |
| 2017 | $10.28M | -53.7% |
| 2016 | $22.19M | -41.7% |
| 2015 | $38.07M | +158.3% |
| 2014 | $14.74M | -5.4% |
| 2013 | $15.58M | +436.0% |
| 2012 | $2.91M | -49.3% |
| 2011 | $5.73M | -15.3% |
| 2010 | $6.77M | -8.6% |
| 2009 | $7.41M | +119.4% |
| 2008 | -$38.18M | -93.9% |
| 2007 | -$19.69M | -242.8% |
| 2006 | -$5.74M | -747.2% |
| 2005 | -$678.0K | -9.5% |
| 2004 | -$619.0K | -438.3% |
| 2003 | -$115.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $486.79M | +42.2% | +41.7% |
| June 30, 2025 | $343.64M | +1285.7% | -5.8% |
| March 31, 2025 | $364.73M | +5266.8% | -4.6% |
| December 31, 2024 | $382.22M | +932.5% | +11.6% |
| September 30, 2024 | $342.37M | +801.7% | +1281.4% |
| June 30, 2024 | -$28.98M | -173.9% | -310.6% |
| March 31, 2024 | -$7.06M | -117.4% | -706000.0% |
| January 31, 2024 | $1.0K | — | -100.0% |
- Oruka Therapeutics, Inc. showed an increase of +23.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2003–2025 period, Oruka Therapeutics, Inc.’s stockholders equity has grown by 410473.9% (from -$115.0 thousand to $471.93 million).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: